Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events

Journal of Postgraduate Medicine

Volumn 55, Issue 4, 2009, Pages 252-256

  Thomson, V S ^a   John, B ^a   George, P ^a   Joseph, G ^a   Jose, J ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Aspirin resistance; Myocardial infarction; Platelet aggregation

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASPIRIN RESISTANCE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; STROKE; TERTIARY HEALTH CARE; URINALYSIS; URINE LEVEL;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 77249157795     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.58927     Document Type: Article

References (23)

1. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of Aspirin? Could it be Thromboxane A2? Circulation 2002;105:1620-1622
2. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Analysis of multiple thromboxane metabolites in plasma and urine. Adv Prostaglandin Thromboxane Leukot Res 1987;17:611-614
3. Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) study. Am Heart J 2009;157:658-665
4. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708
5. Bruno A, McConnell JP, Cohen SN, Tietjen GE, Wallis RA, Gorelick PB, et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 2004;35:727-730
6. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992;23:1400-1403
7. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002;13:49-56.
8. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammeresi C, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular diseases per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69-75.
9. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014-3019
10. Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003;326:82-83
11. Reilly MP, Praticò D, Delanty N, DiMinno G, Tremoli E, Rader D, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998;98:2822-2828
12. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-1218
13. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006;151:976-1011
14. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998;79:691-705.
15. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258-1263
16. Dussaillant NG, Zapata MM, Fardella BP, Conte LG, Cuneo VM. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chil 2005;133:409-417
17. Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007;41:737-741
18. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655
19. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: Determinants and effect on cardiovascular risk. Circulation 2008;118:1705-1712
20. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965 (Pubitemid 36315537)
21. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS, et al. Profile and prevalence of Indian patients with coronary artery disease. Indian Heart J 2005;57:658-661
22. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 2001;14:57-8,61-62
23. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-993